AbCellera Appoints Ester Falconer, Ph.D., as Chief Technology Officer
February 11 2021 - 4:05PM
Business Wire
AbCellera (Nasdaq: ABCL) announced today that Ester Falconer,
Ph.D., has been appointed as Chief Technology Officer (CTO),
effective January 28, 2021.
As CTO, Dr. Falconer will lead AbCellera’s long-term strategy in
the development, aggregation, and integration of technologies that
improve the speed and success of therapeutic antibody discovery
from target to investigational new drug application submission.
“Dr. Falconer is an accomplished and creative technologist whose
contributions have been indispensable to AbCellera’s success. She
is also one of our strongest leaders and an effective mentor with a
proven ability to build high-performing teams,” said Carl Hansen,
Ph.D., CEO of AbCellera. “We welcome her to the executive team and
are fortunate to have her leading our platform development.”
Prior to her promotion to CTO, Dr. Falconer was the Head of
Research and Development, overseeing technology development in
genomics, microfluidics, biochemistry, protein engineering, data
sciences, and machine learning. She led the development of
AbCellera’s Pandemic Preparedness Platform (P3) program and its
deployment to combat COVID-19. This resulted in the discovery and
development of bamlanivimab, the first monoclonal antibody therapy
to receive Emergency Use Authorization (EUA) by U.S. Food and Drug
Administration (FDA) to treat COVID-19, which has been authorized
in more than eight countries and used to treat more than 125,000
patients.
“AbCellera is an exceptional company of talented people driving
incredible technology advances,” said Dr. Falconer. “I am excited
and honoured to continue developing our platform with this team, in
our overall mission to power drug development for partners and
ultimately for patients.”
Dr. Falconer joined AbCellera in 2015 as Senior Research
Scientist, and subsequently advanced to become Group Leader of
Molecular Biology and Antibody Expression in 2017, and Head of
Research and Development in 2019. She earned a Ph.D. in genetics
and cell biology from the University of British Columbia in 2005.
Dr. Falconer completed a postdoctoral fellowship in stem cell
biology and cancer research in 2015 that led to development of
single cell technologies to map genomic rearrangements, applicable
to genomic instability, genome assembly, and long-range
haplotyping.
About AbCellera Biologics Inc.
AbCellera is a technology company that searches, decodes, and
analyzes natural immune systems to find antibodies that its
partners can develop into drugs to prevent and treat disease.
AbCellera partners with drug developers of all sizes, from large
pharmaceutical to small biotechnology companies, empowering them to
move quickly, reduce cost, and tackle the toughest problems in drug
development. For more information, visit www.abcellera.com.
AbCellera Forward-looking Statements
This press release contains forward-looking statements,
including statements made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. The
forward-looking statements are based on management’s beliefs and
assumptions and on information currently available to management.
All statements contained in this release other than statements of
historical fact are forward-looking statements, including
statements regarding our ability to develop, commercialize and
achieve market acceptance of our current and planned products and
services, our research and development efforts, and other matters
regarding our business strategies, use of capital, results of
operations and financial position, and plans and objectives for
future operations.
In some cases, you can identify forward-looking statements by
the words “may,” “will,” “could,” “would,” “should,” “expect,”
“intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,”
“project,” “potential,” “continue,” “ongoing” or the negative of
these terms or other comparable terminology, although not all
forward-looking statements contain these words. These statements
involve risks, uncertainties and other factors that may cause
actual results, levels of activity, performance, or achievements to
be materially different from the information expressed or implied
by these forward-looking statements. These risks, uncertainties and
other factors are described under "Risk Factors," "Management's
Discussion and Analysis of Financial Condition and Results of
Operations" and elsewhere in the documents we file with the
Securities and Exchange Commission from time to time. We caution
you that forward-looking statements are based on a combination of
facts and factors currently known by us and our projections of the
future, about which we cannot be certain. As a result, the
forward-looking statements may not prove to be accurate. The
forward-looking statements in this press release represent our
views as of the date hereof. We undertake no obligation to update
any forward-looking statements for any reason, except as required
by law.
Source: AbCellera Biologics Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210211005842/en/
Inquiries Media: Jessica Yingling, Ph.D.;
media@abcellera.com, +1(236)521-6774 Business Development:
Kevin Heyries, Ph.D.; bd@abcellera.com, +1(604)559-9005 Investor
Relations: Melanie Solomon; ir@abcellera.com,
+1(778)729-9116
AbCellera Biologics (NASDAQ:ABCL)
Historical Stock Chart
From Aug 2024 to Sep 2024
AbCellera Biologics (NASDAQ:ABCL)
Historical Stock Chart
From Sep 2023 to Sep 2024